Caris Life Sciences Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board elections and auditor ratification, with all proposals approved. No shareholder questions were submitted, and final voting results will be published in a Form 8-K filing.
-
Strong revenue and volume growth driven by differentiated, FDA-approved molecular profiling and AI-powered platforms. Strategic investments, expanded partnerships, and new product launches position the company for continued leadership and profitability in precision oncology.
-
Q1 2026 saw 79% revenue growth to $216M, driven by clinical profiling and new launches. Gross margin rose to 65%, with positive adjusted EBITDA and free cash flow. Guidance for strong volume and revenue growth is reaffirmed, supported by a robust pipeline and expanded sales force.
-
Strong financial results and cash position support aggressive investment in technology, commercial expansion, and a robust product pipeline. Early detection and MCED programs are advancing, with new partnerships and market penetration expected to drive growth in 2026 and beyond.
Fiscal Year 2025
-
Q4 and full-year 2025 saw record revenue and profitability, driven by strong molecular profiling growth, improved ASPs, and expanding clinical volumes. 2026 guidance projects continued double-digit growth, positive cash flow, and major investments in early detection and commercial expansion.
-
Q3 2025 saw 113% revenue growth, record profitability, and margin expansion, driven by strong clinical profiling and higher ASPs. Guidance for FY25 was raised, with continued investment in early detection, MRD, and data platforms.
-
Q2 2025 saw 81% revenue growth to $181.4M, driven by clinical and pharma segments, with gross margin up to 62.7%. Positive adjusted EBITDA and free cash flow were achieved, and FY 2025 revenue is guided to $675M–$685M, with strong growth expected in both volumes and ASPs.